Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Johnson & Johnson : Abandoning Insulin Pumps

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 02:28pm CEST
By Cara Lombardo 

Johnson & Johnson's Animas Corp. will close and exit the insulin pump business, the company said Thursday, citing increased competition that made selling the pumps unsustainable.

Sales of its Animas Vibe and OneTouch Ping pumps in the U.S. and Canada are discontinued immediately, the company said in a news release. The company said it is still evaluating the timing on exiting markets outside the U.S. and Canada.

J&J said the 90,000 diabetes patients that use Animas products will be offered the option to transfer to a pump from Medtronic PLC. Medtronic has seen demand for its pumps skyrocket after the U.S. Food and Drug and Administration approved two new pumps -- the MiniMed 630G and MiniMed 670G -- within weeks of each other last year.

J&J has been streamlining its business as part of a strategic review. Earlier this year, Chief Executive Alex Gorsky had said the company was evaluating options for its diabetes businesses, including possible sales. The company recorded a $200 million charge in its second quarter, primarily related to the insulin pump business.

J&J said it is continuing to evaluate options for its other diabetes businesses including LifeScan Inc., which makes blood-glucose monitors, and OneTouch products.

"This decision was extremely difficult and comes following the extensive exploration of all other viable options for the Animas business," said Valerie Asbury, general manager of Animas, in prepared remarks.

Animas employs 410 people, but the company didn't say if employees would be laid off.

Write to Cara Lombardo at [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON -0.07% 125.85 Delayed Quote.-9.93%
MEDTRONIC PLC -0.45% 88.02 Delayed Quote.9.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
07/21JOHNSON & JOHNSON : to Present New Data for Investigational Preventive Vaccine, ..
AQ
07/21JOHNSON & JOHNSON : Janssen gets indication expansion approval to treat CLL/ SLL
AQ
07/20JOHNSON & JOHNSON : Zach attack tames cold and wet Carnoustie
AQ
07/20JOHNSON & JOHNSO : johnson, & johnson
PU
07/20JOHNSON & JOHNSON : Janssen Pharmaceutical - Phase 3 CREDENCE Renal Outcomes Tri..
AQ
07/20JOHNSON & JOHNSON : Announces Quarterly Dividend for Third Quarter 2018
AQ
07/20Eversight Expands Offer Innovation Suite to Address $760 Billion Consumer Pac..
AQ
07/20JOHNSON & JOHNSON : BioCentury - Provention raises $64M IPO
AQ
07/20JOHNSON & JOHNSON : and Reports 2018 Second-Quarter Results
AQ
07/20JOHNSON & JOHNSON : Bayer - Phil Sharp to join Bayer UK and Ireland
AQ
More news
News from SeekingAlpha
09:00aTHE PASSIVE DGI CORE PORTFOLIO : Midyear Review 
07/21STOCKS TO WATCH : FANGs Out In Tech 
07/20QUARTERLY REVIEW OF DIVGRO : Q2 2018 
07/20FDA releases updated industry guidelines for development of generic abuse-det.. 
07/20YOUR DAILY PHARMA SCOOP : Catalyst Bio Succeeds, CTI Moves Forward, Pfizer Posit.. 
Financials ($)
Sales 2018 81 273 M
EBIT 2018 24 895 M
Net income 2018 16 036 M
Debt 2018 12 563 M
Yield 2018 2,83%
P/E ratio 2018 18,32
P/E ratio 2019 16,47
EV / Sales 2018 4,31x
EV / Sales 2019 4,05x
Capitalization 338 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 143 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-9.93%337 790
PFIZER3.06%218 540
NOVARTIS-1.75%206 705
ROCHE HOLDING LTD.-5.90%200 737
MERCK AND COMPANY11.11%168 171
AMGEN9.54%126 889